<PAGE>
________________________________________________________________________________
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) FEBRUARY 22, 2000
-------------------
ENZON, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
-------------------
<TABLE>
<S> <C> <C>
DELAWARE 0-12957 22-237286
(STATE OR OTHER JURISDICTION (COMMISSION (IRS EMPLOYER
OF INCORPORATION) FILE NUMBER) IDENTIFICATION)
</TABLE>
<TABLE>
<S> <C>
20 KINGSBRIDGE ROAD 08854
PISCATAWAY, NEW JERSEY (ZIP CODE)
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
</TABLE>
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE (732) 980-4500
-------------------
________________________________________________
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)
________________________________________________________________________________
<PAGE>
ITEM 5. OTHER EVENTS
On February 22, 2000, Enzon, Inc. issued a press release, a copy of which is
attached as Exhibit 99.1 and incorporated by reference herein.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibit 99.1 -- Press Release dated February 22, 2000.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: February 22, 2000
ENZON, INC.
(Registrant)
By: /s/ KENNETH J. ZUERBLIS
..................................
KENNETH J. ZUERBLIS
VICE PRESIDENT, FINANCE
AND CHIEF FINANCIAL OFFICER
<PAGE>
EXHIBIT 99.1
NEWS RELEASE
ENZON ANNOUNCES PUBLIC OFFERING
PISCATAWAY, NEW JERSEY, February 22, 2000, Enzon, Inc. (NASDAQ: ENZN)
announced today that it has filed a registration statement with the Securities
and Exchange Commission for a proposed offering of 2,000,000 shares of its
common stock.
The offering is being underwritten by Morgan Stanley Dean Witter, CIBC World
Markets and SG Cowen Securities Corporation. The Company will grant the
underwriters an option to purchase up to an additional 15% of the shares being
offered at the public offering price, less an underwriting discount, solely to
cover over-allotments.
A registration statement relating to these securities has been filed with
the Securities and Exchange Commission but has not yet become effective. These
securities may not be sold nor may offers to buy be accepted prior to the time
the registration statement becomes effective. This press release shall not
constitute an offer to sell or a solicitation of an offer to buy nor shall there
be any sale of these securities in any state in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under the
securities laws of any such state.
A copy of the Prospectus relating to the offering may be obtained from
Morgan Stanley Dean Witter, Attn: Prospectus Department, 1585 Broadway, New
York, New York, 10036-8293, when available. The registration statement can also
be viewed on the Internet at http://www.sec.gov.
Enzon is a biopharmaceutical company developing advanced therapeutics for
life-threatening diseases through the application of its proprietary drug
delivery and targeting technologies, PEG Modification, Pro Drug/Transport
technology and Single-Chain Antigen-Binding (SCA'r') protein technology. Enzon
has several products in various stages of clinical development by itself and
with partners, including PEG-INTRON with Schering-Plough, which is in Phase III
clinical trials for malignant melanoma, chronic myelogenous leukemia and in
combination treatment with Schering-Plough's product REBETOL'r' for the
treatment for hepatitis C. Schering-Plough has filed for marketing approval in
the U.S. and Europe for PEG-INTRON for the treatment of chronic hepatitis C.
Enzon also has two products on the market, ONCASPAR, which is used to treat
Acute Lymphoblastic Leukemia (ALL), and ADAGEN, a treatment for a form of Severe
Combined Immunodeficiency Disease (SCID) commonly known as the 'Bubble Boy
Disease.' Enzon develops and markets products on its own and through strategic
alliances, which in addition to Schering-Plough Corporation include Alexion
Pharmaceuticals, Inc., Baxter Healthcare Corporation, Bristol-Myers Squibb
Company, Eli Lilly & Company, and Rhone-Poulenc Rorer Pharmaceuticals, Inc.
Certain statements made in this press release related to potential
government approvals, market potential, commercialization and sales revenues of
medical products and biologics, as well as their therapeutic applications and
outcomes, are forward-looking and are made pursuant to the safe harbor
provisions of the Securities Litigation Reform Act of 1995. Such statements
involve risks and uncertainties, which may differ materially from those set
forth in these statements. In addition, the economic, competitive, governmental,
technological and other factors identified in the Company's filings with the
Securities and Exchange Commission could affect such results.
This release is also available at http://www.enzon.com
